FDA Issues Complete Response Letter to Alimera Sciences Regarding New Drug Application for ILUVIEN
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it received a Complete Response Letter (CRL) from the U.S. Food a...